Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 5/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.33 |
| ▸ | DHFR | P00374 | 1/20 | 0.33 |
| ▸ | TACR3 | P29371 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21765816 | 0.99 | TACR3 (0.34) | SLC6A3SLC6A2SLC6A4DHFRTACR3 | |
| SCHEMBL21765760 | 0.98 | SLC6A3 (0.30) | SLC6A3SLC6A2SLC6A4DHFRTACR3 | |
| SCHEMBL21765625 | 0.96 | KMT2A (0.32) | TACR3 | |
| SCHEMBL21765811 | 0.96 | SLC6A3 (0.31) | SLC6A3SLC6A2SLC6A4DHFR | |
| SCHEMBL21765778 | 0.95 | KMT2A (0.33) | SLC6A3 | |
| SCHEMBL21747380 | 0.85 | EGLN1 (0.32) | — | |
| SCHEMBL25543919 | 0.85 | EGLN1 (0.32) | — | |
| SCHEMBL21747271 | 0.84 | KMO (0.32) | — | |
| SCHEMBL25543925 | 0.84 | NPC1 (0.32) | — | |
| SCHEMBL21765753 | 0.82 | KMT2A (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11970495-B2 | Indolizine derivatives and their application in medicine | KIND PHARMACEUTICAL (CN) | 2024-04-30 | — | — | US | disclosed |
| US-11945817-B2 | Indolizine derivatives and their application in medicine | KIND PHARMACEUTICAL (CN) | 2024-04-02 | — | — | US | disclosed |
| US-20230257379-A1 | INDOLIZINE DERIVATIVES AND THEIR APPLICATION IN MEDICINE | KIND PHARMACEUTICAL (CN) | 2023-08-17 | — | — | US | disclosed |
| US-20230257379-A1 | INDOLIZINE DERIVATIVES AND THEIR APPLICATION IN MEDICINE | KIND PHARMACEUTICAL (CN) | 2023-08-17 | — | — | US | disclosed |
| US-20230242527-A1 | INDOLIZINE DERIVATIVES AND THEIR APPLICATION IN MEDICINE | KIND PHARMACEUTICAL (CN) | 2023-08-03 | — | — | US | disclosed |
| US-20230242527-A1 | INDOLIZINE DERIVATIVES AND THEIR APPLICATION IN MEDICINE | KIND PHARMACEUTICAL (CN) | 2023-08-03 | — | — | US | disclosed |
| US-11655249-B2 | Indolizine derivatives and their application in medicine | KIND PHARMACEUTICAL (CN) | 2023-05-23 | — | — | US | disclosed |
| US-11655249-B2 | Indolizine derivatives and their application in medicine | KIND PHARMACEUTICAL (CN) | 2023-05-23 | — | — | US | disclosed |
| EP-3613742-B1 | INDOLIZINE DERIVATIVES AND APPLICATION THEREOF IN MEDICINE | KIND PHARMACEUTICAL (CN) | 2022-12-07 | — | — | EP | disclosed |
| US-20210253570-A1 | INDOLIZINE DERIVATIVES AND THEIR APPLICATION IN MEDICINE | KIND PHARMACEUTICAL (CN) | 2021-08-19 | — | — | US | disclosed |
| CN-113004271-A | Indolizine derivative and application thereof in medicine | 杭州安道药业有限公司 | 2021-06-22 | — | — | CN | disclosed |
| US-11021478-B2 | Indolizine derivatives and their application in medicine | KIND PHARMACEUTICAL (CN) | 2021-06-01 | — | — | US | disclosed |
| CN-108484598-B | Indolizine derivative and application thereof in medicine | 杭州安道药业有限公司 | 2021-03-02 | — | — | CN | disclosed |
| US-20200165242-A1 | INDOLIZINE DERIVATIVES AND THEIR APPLICATION IN MEDICINE | KIND PHARMACEUTICAL (CN) | 2020-05-28 | — | — | US | disclosed |
| EP-3613742-A1 | INDOLIZINE DERIVATIVES AND APPLICATION THEREOF IN MEDICINE | Kind Pharmaceutical (CN) | 2020-02-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230257379-A1 | INDOLIZINE DERIVATIVES AND THEIR APPLICATION IN MEDICINE | INMT, IDO1, IDO2 | SLC6A3 132/4885SLC6A2 48/4885SLC6A4 28/4885 |
| US-11021478-B2 | Indolizine derivatives and their application in medicine | INMT, IDO1, IDO2 | SLC6A3 132/4885SLC6A2 48/4885SLC6A4 28/4885 |
| US-11970495-B2 | Indolizine derivatives and their application in medicine | INMT, IDO1, IDO2 | SLC6A3 132/4885SLC6A2 48/4885SLC6A4 28/4885 |
| US-20230242527-A1 | INDOLIZINE DERIVATIVES AND THEIR APPLICATION IN MEDICINE | INMT, IDO1, IDO2 | SLC6A3 132/4885SLC6A2 48/4885SLC6A4 28/4885 |
| US-11945817-B2 | Indolizine derivatives and their application in medicine | INMT, IDO1, IDO2 | SLC6A3 132/4885SLC6A2 48/4885SLC6A4 28/4885 |
| US-20210253570-A1 | INDOLIZINE DERIVATIVES AND THEIR APPLICATION IN MEDICINE | INMT, IDO1, IDO2 | SLC6A3 132/4885SLC6A2 48/4885SLC6A4 28/4885 |
| US-11655249-B2 | Indolizine derivatives and their application in medicine | INMT, IDO1, IDO2 | SLC6A3 132/4885SLC6A2 48/4885SLC6A4 28/4885 |
| US-20200165242-A1 | INDOLIZINE DERIVATIVES AND THEIR APPLICATION IN MEDICINE | INMT, IDO1, IDO2 | SLC6A3 132/4885SLC6A2 48/4885SLC6A4 28/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.